Gossamer Bio Ties $250 Million Financing to FDA Milestones After Mixed PROSERA Result

Company: Gossamer Bio · Event Type: Milestone-Tranched Private Placement · Lead Asset: Seralutinib · Indication: Pulmonary Arterial Hypertension · Date: August 21, 2026 Summary Gossamer Bio has structured a private placement of up to $250 million with financing explicitly tranched to regulatory and commercial milestones…